Trial Profile

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 31 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 59872 (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions; Pharmacodynamics
Sponsors Incyte Corporation

Most Recent Events

24 Oct 2018 Status changed from recruiting to discontinued due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.
15 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
15 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com